FluoGuide Chooses Laser for Photothermal Cancer Therapy with FG001

FluoGuide A/S, a biotechnology company based in Copenhagen, Denmark, has recently announced its decision to utilize a laser system for the development of photothermal therapy (PTT). The company, listed on the Stockholm Stock Exchange under the ticker FLUO, specializes in precision cancer surgery and has made significant strides in this field with its lead product, FG001.

FG001 is a fluorescent agent designed to target the urokinase-type plasminogen activator receptor (uPAR), which is commonly found in cancer cells. This specificity allows FG001 to effectively identify and bind to malignant cells, providing surgeons with a visual guide to distinguish cancerous tissue from healthy tissue. Clinical data have validated FG001's effectiveness in enhancing surgical precision for three types of cancer: aggressive brain cancer, head and neck cancer, and lung cancer.

Beyond its role in surgical guidance, FG001 also possesses photothermal therapy properties. This means that, when activated by near-infrared light, FG001 can generate heat sufficient to kill cancer cells. This dual functionality not only aids in the accurate removal of tumors but also has the potential to improve overall patient outcomes by destroying cancer cells that might not be surgically accessible.

The newly selected laser system is crucial for the activation of FG001's PTT capabilities. It provides the specific light wavelength required to trigger FG001, thereby enhancing its therapeutic efficacy. This system's versatility and power make it suitable for a range of applications, including the treatment of local cancer recurrences and inoperable cancers.

"We have now selected the laser system to support the further development of FG001 as photothermal cancer therapy. This application holds considerable potential for improving cancer treatment and outcomes for patients," stated Morten Albrechtsen, CEO of FluoGuide.

As part of their ongoing efforts, FluoGuide is also exploring the economic viability and potential synergies of combining PTT with their current phase III program for fluorescence-guided surgery in aggressive brain cancer. This type of cancer is known to recur locally in more than 90% of patients, highlighting a significant unmet need for improved surgical outcomes. Preliminary clinical data suggest that FG001 is both safe and well-tolerated, enhancing the precision of tumor removal while preserving healthy tissue.

FluoGuide's strategic decision to incorporate this laser system into their PTT development marks a significant step forward in the fight against cancer. By leveraging the dual capabilities of FG001, the company aims to set a new standard in precision cancer therapy, offering hope for better treatment outcomes and improved quality of life for cancer patients.